

February 6, 2020

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-005540-28 / Novartis Protocol ID CLJM716X2104

A phase Ib/II, multicenter study of LJM716 in combination with cetuximab in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma

Trial CLJM716X2104 cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.